Skip to main content

ForgingBridges | NULIBRY Access and Support helps your child access NULIBRY therapy

Fill out the enrollment form with your healthcare provider to register your child.

Sign up today

Download Enrollment Form
forging bridges access support program logo

ForgingBridges | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-55BRIDGE
(1-888-552-7434)

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

Continuing Support

Supporting you and your child doesn't stop when you have left the hospital and gone home. ForgingBridges | NULIBRY is with you every step of the way. A trained member of the ForgingBridges staff will contact you to assess any medication needs you may have. You will be contacted regularly to make sure things are going smoothly, and to ask about any questions that may have come up.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

ADVERSE REACTIONS

The most common adverse reactions in NULIBRY-treated patients were infusion catheter–related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION

Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.